RPS21 and MYL6B in RI were associated with poor prognosis of patients with ESCA; they have been validated as oncoproteins in prostate tumor and hepatocellular carcinoma, respectively [23, 24]. Here, RPS21 is linked to hepatocellular carcinoma.